Cargando…
Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank
BACKGROUND: Frailty, a state of reduced physiological reserve, is common in people with chronic obstructive pulmonary disease (COPD). Frailty can occur at any age; however, the implications in younger people (eg, aged <65 years) with COPD are unclear. We assessed the prevalence of frailty in UK B...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255399/ https://www.ncbi.nlm.nih.gov/pubmed/35787523 http://dx.doi.org/10.1136/bmjresp-2022-001314 |
_version_ | 1784740913795301376 |
---|---|
author | Hanlon, Peter Lewsey, James Quint, Jennifer K Jani, Bhautesh D Nicholl, Barbara I McAllister, David A Mair, Frances S |
author_facet | Hanlon, Peter Lewsey, James Quint, Jennifer K Jani, Bhautesh D Nicholl, Barbara I McAllister, David A Mair, Frances S |
author_sort | Hanlon, Peter |
collection | PubMed |
description | BACKGROUND: Frailty, a state of reduced physiological reserve, is common in people with chronic obstructive pulmonary disease (COPD). Frailty can occur at any age; however, the implications in younger people (eg, aged <65 years) with COPD are unclear. We assessed the prevalence of frailty in UK Biobank participants with COPD; explored relationships between frailty and forced expiratory volume in 1 second (FEV1) and quantified the association between frailty and adverse outcomes. METHODS: UK Biobank participants (n=3132, recruited 2006–2010) with COPD aged 40–70 years were analysed comparing two frailty measures (frailty phenotype and frailty index) at baseline. Relationship with FEV1 was assessed for each measure. Outcomes were mortality, major adverse cardiovascular event (MACE), all-cause hospitalisation, hospitalisation with COPD exacerbation and community COPD exacerbation over 8 years of follow-up. RESULTS: Frailty was common by both definitions (17% frail using frailty phenotype, 28% moderate and 4% severely frail using frailty index). The frailty phenotype, but not the frailty index, was associated with lower FEV1. Frailty phenotype (frail vs robust) was associated with mortality (HR 2.33; 95% CI 1.84 to 2.96), MACE (2.73; 1.66 to 4.49), hospitalisation (incidence rate ratio 3.39; 2.77 to 4.14) hospitalised exacerbation (5.19; 3.80 to 7.09) and community exacerbation (2.15; 1.81 to 2.54), as was frailty index (severe vs robust) (mortality (2.65; 95% CI 1.75 to 4.02), MACE (6.76; 2.68 to 17.04), hospitalisation (3.69; 2.52 to 5.42), hospitalised exacerbation (4.26; 2.37 to 7.68) and community exacerbation (2.39; 1.74 to 3.28)). These relationships were similar before and after adjustment for FEV1. CONCLUSION: Frailty, regardless of age or measure, identifies people with COPD at risk of adverse clinical outcomes. Frailty assessment may aid risk stratification and guide-targeted intervention in COPD and should not be limited to people aged >65 years. |
format | Online Article Text |
id | pubmed-9255399 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-92553992022-07-20 Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank Hanlon, Peter Lewsey, James Quint, Jennifer K Jani, Bhautesh D Nicholl, Barbara I McAllister, David A Mair, Frances S BMJ Open Respir Res Chronic Obstructive Pulmonary Disease BACKGROUND: Frailty, a state of reduced physiological reserve, is common in people with chronic obstructive pulmonary disease (COPD). Frailty can occur at any age; however, the implications in younger people (eg, aged <65 years) with COPD are unclear. We assessed the prevalence of frailty in UK Biobank participants with COPD; explored relationships between frailty and forced expiratory volume in 1 second (FEV1) and quantified the association between frailty and adverse outcomes. METHODS: UK Biobank participants (n=3132, recruited 2006–2010) with COPD aged 40–70 years were analysed comparing two frailty measures (frailty phenotype and frailty index) at baseline. Relationship with FEV1 was assessed for each measure. Outcomes were mortality, major adverse cardiovascular event (MACE), all-cause hospitalisation, hospitalisation with COPD exacerbation and community COPD exacerbation over 8 years of follow-up. RESULTS: Frailty was common by both definitions (17% frail using frailty phenotype, 28% moderate and 4% severely frail using frailty index). The frailty phenotype, but not the frailty index, was associated with lower FEV1. Frailty phenotype (frail vs robust) was associated with mortality (HR 2.33; 95% CI 1.84 to 2.96), MACE (2.73; 1.66 to 4.49), hospitalisation (incidence rate ratio 3.39; 2.77 to 4.14) hospitalised exacerbation (5.19; 3.80 to 7.09) and community exacerbation (2.15; 1.81 to 2.54), as was frailty index (severe vs robust) (mortality (2.65; 95% CI 1.75 to 4.02), MACE (6.76; 2.68 to 17.04), hospitalisation (3.69; 2.52 to 5.42), hospitalised exacerbation (4.26; 2.37 to 7.68) and community exacerbation (2.39; 1.74 to 3.28)). These relationships were similar before and after adjustment for FEV1. CONCLUSION: Frailty, regardless of age or measure, identifies people with COPD at risk of adverse clinical outcomes. Frailty assessment may aid risk stratification and guide-targeted intervention in COPD and should not be limited to people aged >65 years. BMJ Publishing Group 2022-07-04 /pmc/articles/PMC9255399/ /pubmed/35787523 http://dx.doi.org/10.1136/bmjresp-2022-001314 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Chronic Obstructive Pulmonary Disease Hanlon, Peter Lewsey, James Quint, Jennifer K Jani, Bhautesh D Nicholl, Barbara I McAllister, David A Mair, Frances S Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank |
title | Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank |
title_full | Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank |
title_fullStr | Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank |
title_full_unstemmed | Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank |
title_short | Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank |
title_sort | frailty in copd: an analysis of prevalence and clinical impact using uk biobank |
topic | Chronic Obstructive Pulmonary Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255399/ https://www.ncbi.nlm.nih.gov/pubmed/35787523 http://dx.doi.org/10.1136/bmjresp-2022-001314 |
work_keys_str_mv | AT hanlonpeter frailtyincopdananalysisofprevalenceandclinicalimpactusingukbiobank AT lewseyjames frailtyincopdananalysisofprevalenceandclinicalimpactusingukbiobank AT quintjenniferk frailtyincopdananalysisofprevalenceandclinicalimpactusingukbiobank AT janibhauteshd frailtyincopdananalysisofprevalenceandclinicalimpactusingukbiobank AT nichollbarbarai frailtyincopdananalysisofprevalenceandclinicalimpactusingukbiobank AT mcallisterdavida frailtyincopdananalysisofprevalenceandclinicalimpactusingukbiobank AT mairfrancess frailtyincopdananalysisofprevalenceandclinicalimpactusingukbiobank |